Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

455results about How to "Increase drug concentration" patented technology

Pharmaceutical compositions of dispersions of drugs and neutral polymers

In one aspect, pharmaceutical compositions comprising dispersions of an acid-sensitive drug and a neutral dispersion polymer are disclosed. The acid-sensitive drug has improved chemical stability relative to dispersions of the drug and acidic polymers. In another aspect, pharmaceutical compositions of low-solubility drugs and amphiphilic, hydroxy-functional vinyl copolymers are disclosed.
Owner:BEND RES

Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials

ActiveUS20050031693A1Improve dissolve concentrationImproved dissolved concentration of drugPowder deliveryDrug compositionsDrugLipophilicity
A pharmaceutical composition comprises a solid adsorbate comprising a drug adsorbed onto a substrate and a lipophilic microphase-forming material. The solid adsorbate may also be co-administered with a lipophilic microphase-forming material to an in vivo use environment. The compositions of the present invention enhance the concentration of drug in a use environment.
Owner:BEND RES

Transdermal Delivery of Meptazinol

A delivery system for the delivery of a salt of meptazinol or meptazinol precursor which increases the bioavailability of meptanizol by an effective amount to provide analgesic relief is disclosed. One embodiment of the delivery system is a transdermal device which increases the skin flux of meptazinol by an effective amount to provide analgesic relief. Also disclosed are methods of providing analgesic relief.
Owner:SHIRE PHARMA INC

Use of nano structured lipid carrier drug feeding system

The invention discloses an application of nanometer structure lipid carrier administration system in the antineoplastic drug to reverse the multiple-drug tolerance of tumour cell, which comprises the following parts: solid lipid material, liquid lipid material and antineoplastic drug, wherein the rate of the liquid lipid (such as oleic acid) is 0-30wt%; the solid lipid is selected from monoglyceride; the liquid lipid is oleic acid; the antineoplastic drug is Paclitaxel or adriablastina. The invention has highly effective cell uptaking and cytolymph condensing function with packing molecular target in the antineoplastic drug of cell, which avoids P-glucoprotein in the drug tolerant cytolymph from identifying the antineoplastic drug to reduce exclusion.
Owner:ZHEJIANG UNIV

Solid pharmaceutical dispersions with enhanced bioavailability

InactiveUS8263128B2Improve bioavailabilityPreventing and retarding ratePowder deliveryBiocideAcetic acidHydroxypropylmethylcellulose acetate succinate
Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and / or biavailability in a use environment.
Owner:BEND RES

Solid pharmaceutical dispersions with enhanced bioavailability

InactiveUS8257741B2Improve solubilityEffective dispersionPowder deliveryBiocideAcetic acidHydroxypropylmethylcellulose acetate succinate
Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and / or biavailability in a use environment.
Owner:BEND RES

Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds

[Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property).[Solving Means] The pharmaceutical composition of the present invention is a pharmaceutical composition comprising a nitrogen-containing fused ring compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable additives, wherein the nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof is not in contact with a basic additive:wherein each symbol is as described in the specification.
Owner:JAPAN TOBACCO INC

"Micro-Patch" for Assessment of the Local Microvasculature and Microcirculatory Vasoreactivity

A method for interrogating the microcirculation of a subject for use in characterizing function in health and disease, monitor changes in microcirculation over time, and identify responses in microcirculation to potentially harmful or beneficial interventions. The method includes delivering a study agent to a study surface for trans-surface delivery to the microvasculature of the subject and monitoring the microvasculature of the subject in the area of the study surface. A system is also provided which includes a micro-patch for delivery of study agent to a study surface for trans-surface delivery to the microvasculature of the subject and a monitoring probe for monitoring the microvasculature of the subject in the area of the study surface.
Owner:SILVERMAN DAVID G

Embolism material composition as well as preparation method and use thereof

The invention provides an embolism material composition as well as preparation method and use thereof, the embolism material composition is prepared from reactant raw materials, wherein the reactant raw materials comprise a biocompatibility material, a roentgenopaque substance and a magnetic resonance imaging substance, the roentgenopaque substance and the magnetic resonance imaging (MRI) substance are covered by the biocompatibility material. The embolism material composition not only can be directly detected by an X-ray image device, but also can be directly detected by the MRI, so that a doctor can select a detection method according to self condition of a patient and the medical device condition.
Owner:HYGEA MEDICAL TECH CO LTD

Human Binding Molecules Having Killing Activity Against Staphylococci and Uses Thereof

ActiveUS20090104204A1Avoid adjustmentInhibiting and reducing spread of StaphylococcusAntibacterial agentsSugar derivativesGenus staphylococcusMolecular biology
The present invention provides human binding molecules specifically binding to staphylococci and having killing activity against staphylococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and / or treatment of a condition resulting from Staphylococcus.
Owner:JANSSEN VACCINES & PREVENTION BV

Human binding molecules having killing activity against staphylococci and uses thereof

The present invention provides human binding molecules specifically binding to staphylococci and having killing activity against staphylococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and / or treatment of a condition resulting from Staphylococcus.
Owner:JANSSEN VACCINES & PREVENTION BV

Pharmaceutical compositions comprising drug and concentration-enhancing polymers

A solubility-improved drug form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same drug form without the concentration-enhancing polymer.
Owner:BEND RES

Micro-emulsion thermosensitive gel for skin external use and preparation method thereof

The invention relates to the technical field of medicines, and in particular relates to a micro-emulsion thermosensitive gel for skin wound healing and a preparation method thereof. The micro-emulsion thermosensitive gel disclosed by the invention is composed of medicines, oil phase, a surfactant, a cosurfactant, a gel matrix and water, wherein the medicines are selected from resveratrol, paeonol and matrine. Proved by animal experiments, the prepared micro-emulsion thermosensitive gel has the characteristics of nearly no irritation to skin, safety in use, large percutaneous infiltration quantity, high percutaneous infiltration rate, long retention time of the micro-emulsion gel in the skin, high medicine concentration in the skin, good slow-release effect and good effect of promoting the healing of skin wound injury. The micro-emulsion thermosensitive gel disclosed by the invention has the advantages of simpleness in preparation method, low cost, convenience and safety in use and capability of effectively promoting the skin wound healing. According to the invention, a novel dosage form is provided for treating the skin wound.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY

Host cell specific binding molecules capable of neutralizing viruses and uses thereof

The present invention provides human binding molecules specifically binding to a host cell protein and having virus neutralizing activity, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and / or treatment of viral infections.
Owner:JANSSEN VACCINES & PREVENTION BV

Cyclic nucleoside phosphate compound and preparation method and application thereof

The invention relates to a cyclic nucleoside phosphate compound in a structure shown as a formula I described in the specification and a preparation method and an application thereof. The cyclic nucleoside phosphate compound in the structure shown as the formula I is a precursor drug with an antivirus effect, wherein X is selected from any one of hydrogen, fluorine, chlorine, bromine and iodine, Y is selected from any one of oxygen and sulfur, and Z is arycyclo or arycyclo with 1-3 substituents; the arycyclo is selected from any one of phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-furyl, 3-furyl, 2-thienyl and 3-thienyl, the substituent on the arycyclo is selected from any one of fluorine, chlorine, bromine, iodine, trifluoromethyl, C1-3 alkyl and -OR, and R is selected from any one of trifluoromethyl and C1-3 alkyl.
Owner:ANHUI BIOCHEM UNITED PHARMA CO LTD

Tenofovir cyclic phosphonate compound and pharmaceutically acceptable salt thereof, and preparation methods and applications thereof

The invention relates to a tenofovir cyclic phosphonate compound having a structure represented by a formula I and a pharmaceutically acceptable salt thereof, and preparation methods and applications thereof, wherein the compound represented by the formula I is a tenofovir pro-drug having a liver targeting character and is used for treatment of hepatitis B and resistance of human immunodeficiency virus infection.
Owner:ANHUI BIOCHEM UNITED PHARMA CO LTD

Liver targeting pharmaceutical composition and its preparation method

The invention relates to a liver targeting pharmaceutical composition. The pharmaceutical composition for liver targeting is characterized in that protein and polyethylene glycol possessing a liver targeting function modifies an antitumor drug loading by liposome. The drug is delivered to a hepatic tissue lesions zone for increasing the drug concentration in the liver tumors position and raising the therapeutic efficacy of the liver tumors.
Owner:SUN YAT SEN UNIV

Host cell specific binding molecules capable of neutralizing viruses and uses thereof

Provided are human binding molecules that specifically bind to a host cell protein and have virus neutralizing activity, nucleic acid molecules encoding such human binding molecules, compositions comprising the human binding molecules, and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and / or treatment of viral infections.
Owner:JANSSEN VACCINES & PREVENTION BV

Binding molecules capable of neutralizing west nile virus and uses thereof

ActiveUS20070042359A1Proper fluiditySlows absorptionVirusesAntibody mimetics/scaffoldsWest Nile virus RNANucleic acid molecule
The invention provides human binding molecules specifically binding to West Nile virus and having West Nile virus neutralizing activity, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, post-exposure prophylaxis and / or treatment of a condition resulting from West Nile virus.
Owner:JANSSEN VACCINES & PREVENTION BV

Photosensitive liposome with encapsulated water-soluble medicament

The invention provides a photosensitive liposome with encapsulated water-soluble medicament, which is composed of temperature-sensitive phospholipid, cholesterol and long circulation material and hollow gold nanoparticle, wherein, the hollow gold nanoparticle has a characteristic absorption peak at the near infrared zone with the wavelength of 700-900 nm, and the particle size distribution of the hollow gold nanoparticle is in the range of 20-100 nm. According to the invention, a brand new photosensitive liposome is composed by wrapping water-soluble medicament and hollow gold nanoparticle with temperature-sensitive liposome. Under the extraneous near infrared light, the wrapped hollow gold nanoparticle generates a photo-thermal treatment effect, simultaneously, the photo-thermal effect controls a rapid site-specific delivery of medicament in a large amount from the photosensitive liposome, thereby blood vessels in the tumour part can be damaged or the tumor cells can be killed effectively with a chemical treatment effect of the medicamen. The drug loaded liposome of the present invention realizes synchronous photo-thermal and medicament molecule treatment effect, and the treatment effect of disease such as tumour is substantially improved, and the invention has clinic applicability and real treatment meaning.
Owner:ZHEJIANG UNIV

Stabilized pharmaceutical solid compositions of low-solubility drugs and poloxamers, and stabilizing polymers

Solid compositions with improved physical stability comprise an amorphous, low-solubility drug, a poloxamer, and a stabilizing polymer. The compositions provide good physical stability during storage and concentration enhancement of dissolved drug when administered to an aqueous environment of use.
Owner:BEND RES

Preparation method of target compound nano particle

InactiveCN102961337AHigh feasibilityEfficient diagnosis and treatment effectPowder deliveryOrganic active ingredientsN dimethylformamidePorphyrin
The invention provides a preparation method of a target compound nano particle, relating to a preparation method of target treatment integration compound nano particles. The invention solves the technical problems of poor carrier stability and small drug-loading quantity of the traditional antineoplastic drugs. The method comprises the following steps of: preparing a methanol solution of an integrated nano particle of a Fe3O4-HCPT@SiO2 coupling porphyrin photosensitizer; and stirring the methanol solution of the integrated nano particle of the Fe3O4-HCPT@SiO2 coupling porphyrin photosensitizer, N,N-dimethylformamide and target biomolecule or antitumor drug for reacting at the room temperature, and centrifuging to obtain the target compound nano particle. Polystyrolsulfon acid (PSS) and 10-hydroxycamptothecine are absorbed on a Fe3O4 magnetic nano particle through a self-assembly mode. The preparation method is high feasibility; the target compound nano particle has a physical target function of the magnetic nano particle and an active target function of further functionally modifying the biomolecule on the surface; and the medicine concentration can be increased under a dual-target function.
Owner:HARBIN INST OF TECH

Cyclic diamine compounds and medicine containing the same

InactiveUS6969711B2Highly soluble in waterImprove biological activityBiocideGroup 5/15 element organic compoundsAcylcoenzyme A cholesterol acyltransferaseSilylene
The present invention offers novel cyclic diamine compounds and a pharmaceutical composition containing the same.The present invention relates to a compound represented by the formula (I) or salt(s) or solvate(s) thereof. (In the formula, is an optionally substituted divalent residue of benzene, pyridine, cyclohexane or naphthalene or is a vinylene group whereAr is an optionally substituted aryl group;X is —NH—, oxygen atom or sulfur atom;Y is —NR1—, oxygen atom, sulfur atom, sulfoxide or sulfone;Z is a single bond or —NR2—;R1 is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group;R2 is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group;l is an integer of from 0 to 15;m is an integer of 2 or 3; andn is an integer of from 0 to 3).The compound of the present invention is useful as a pharmaceutical composition, particuarly as an inhibitor of acyl coenzyme A cholesterol acyltransferase (ACAT).
Owner:KOWA CO LTD

Transdermal Patch Comprising Paroxetine

InactiveUS20080254073A1Side-effect be reduceHigh bioavailabilityBiocideNervous disorderOral medicationDrug concentration
Disclosed relates to a transdermal patch comprising paroxetine that is useful to reduce the side effects accompanied with the initial high drug concentration after oral administration of paroxetine and decrease the broad metabolism of the drug in the liver. Moreover, the transdermal patch comprising paroxetine of the present invention has an excellent skin permeation rate and shows high bioavailability compared with oral administration of the drug.
Owner:IK SU PHARMA

Acid sensitive polymer prodrug, nanoparticles of prodrug and application of nanoparticles

ActiveCN103285400APowerful killingBeneficial for combination therapyPowder deliveryKetone active ingredientsVinyl etherCancer cell
The invention discloses an acid sensitive polymer prodrug, nanoparticles of the prodrug and application of the nanoparticles. In the acid sensitive polymer prodrug, a polymer precursor is a vinyl ether-functionalized water-soluble A-B type two-block polymer; drug molecules are linked with the A-B type two-block polymer through an acetal bond; the acid sensitive polymer prodrug is self-assembled in water solution to form predrug micellar nanoparticles in which a polyethylene glycol hydrophilic chain segment serves as an outer surface and an anti-cancer drug bound to a polymer main chain through the acetal bond serves as a hydrophobic core. The pH sensitive prodrug and the nanoparticles of he prodrug are simple in preparation method, and good in tumor inhibitory effect; the nanoparticles also can efficiently encapsulate another hydrophobic anticancer drug; the kill capability to the cancer cell is enhanced; and the efficiency of endocytosis of the cell to the nanoparticles can be enhanced by coupling specific target molecules onto the surfaces of the nanoparticles. Thus, the inhibitory effect on the tumor cell is enhanced.
Owner:SUZHOU UNIV

Diaminopyrimidine compound and composition containing same

The invention provides a diaminopyrimidine compound and a composition containing the same and discloses the diaminopyrimidine compound shown as in a formula (I) and a drug combination containing the compound or salt thereof acceptable in crystal form and pharmacy, hydrate or solvent complex, stereoisomer, pro-drug or isotope variant. The diaminopyrimidine compound and the composition containing the same have excellent inhibition effect on protein kinase and have better pharmacokinetic parameter characteristics, and drug concentration of the compound in animal bodies can be increased to improve drug efficacy and safety.
Owner:SHENZHEN TARGETRX INC

Anticancer sustained-release agent containing epothilone

The invention relates to anti-cancer drug slow release agent containing epothilone, which consists of slow release microspheres and solvent, wherein the slow release microspheres comprise anti-cancer effective components and slow release accessories; and the solvent is special solvent containing suspending agent. The anti-cancer effective components are combinations of epothilone, epothilone derivative, epothilone B, epothilone D and anticancer drugs selected from phosphoinositide 3-kinase inhibitor, pyrimidine analog and / or DNA repairase inhibitor, and the like; the slow release accessories are biocompatible high molecules such as polylactic acid and copolymer thereof, polyethylene glycol, terminal carboxyl polylactic acid copolymer, di-fatty acid and sebacic acid copolymer, poly (erucic acid dimmer-sebacic acid), poly (fumaric acid-sebacic acid), polifeprosan, polylactic acid, and the like; and the suspending agent is selected from sodium carboxymethyl cellulose and the like when the viscosity of the suspending agent is 100 to 3,000cp (at a temperature of between 20 and 30 DEG C). The anti-cancer effective components and the slow release microspheres can also be made into slow release implant agents, can effectively inhibit tumor growth through injection or placement and energy removal in tumor or tumor periphery, and can also remarkably enhance curative effect of non-operative treatment such as chemicotherapy and the like.
Owner:JINAN SHUAIHUA PHARMA TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products